S

Strand Therapeutics

Develops programmable, long-acting mRNA therapeutics

Associate Scientist 2 - Analytical Development & Operations

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-timeBoston, MA, USAIn-person

About the Job

Requirements

  • A B.S. or advanced degree and at least 2 years of relevant experience are required.
  • Working experience in analytical development operations pertaining to biologics is required.
  • Prior experience with lipid nanoparticles (LNPs) with nucleic acid payloads is required.
  • Strong collaboration and interpersonal skills are required.
  • Ability to multitask and prioritize to meet important deadlines is required.

Responsibilities

  • Analyze internally and externally submitted samples using various analytical methods, including cell-based assays, enzyme-linked immunosorbent assays (ELISAs), reverse transcription polymerase chain reaction (RT-PCR), and liquid chromatography-mass spectrometry (LC-MS).
  • Support the development of analytical methods or novel analytical techniques focused on deep physical characterization of early- and clinical-stage messenger RNA (mRNA) and lipid nanoparticle (LNP) formulations.
  • Use statistical tools to analyze data and independently draw conclusions.
  • Provide analytical support for screening, optimization, and scale-up efforts in mRNA and LNP process development.

Desired Qualifications

  • Experience with analytical methods such as cell-based assays, enzyme-linked immunosorbent assays (ELISAs), reverse transcription polymerase chain reaction (RT-PCR), and/or liquid chromatography-mass spectrometry (LC-MS) is preferred.
  • Familiarity working with a process development team is a plus.

About the Company

Strand Therapeutics

Develops programmable, long-acting mRNA therapeutics

Strand Therapeutics develops programmable, long-acting mRNA therapeutics that aim to treat cancer and other life-threatening diseases. The product works by delivering mRNA engineered with logic-based circuits that sense disease-specific cell signals and activate only in diseased cells, increasing the therapeutic window and reducing harm to healthy cells. This enables multi-functional treatments with targeted action rather than non-specific delivery. The company differentiates itself by its programmable mRNA platform that combines gene-encoded logic with disease targeting to achieve cell-type–restricted activity, potentially allowing for safer and more precise therapies compared with conventional mRNA approaches. Strand Therapeutics pursues collaboration and partnerships to expand its programs and generate revenue through development and commercialization of its proprietary mRNA therapeutics with healthcare providers and institutions.

Company size
51-200
Company stage
Series B
Total funding
$256M
Headquarters
Boston, MA
Founded
2017

Recently Posted Jobs

Explore more opportunities at Strand Therapeutics

See more jobs